AbbVie today announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus placebo for the acute treatment of migraine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback